If you like to see more ideas, please subscribe to the premium service "Value in Corporate Events" here and try the free trial. In this service we cover major earnings events, M&A, IPOs and other significant corporate events with actionable ideas. Furthermore, we provide coverage of situations and names on request!In February, I believed that Hologic, Inc. ( NASDAQ: HOLX ) started to look appealing even as organic growth was slowing. The women's health business saw pandemic related revenues run off, but rep ...

Core Viewpoint - Hologic, Inc. reported adjusted earnings per share (EPS) of $1.03 for Q2 fiscal 2025, matching the previous year's figure and exceeding the Zacks Consensus Estimate by 0.9% [1]. Financial Performance - Revenues for the quarter totaled $1.01 billion, a decrease of 1.2% year over year, but surpassed the Zacks Consensus Estimate by 0.3% [2]. - The company experienced a GAAP loss per share of 8 cents, a significant improvement from a loss of 72 cents in Q2 fiscal 2024 [1]. Revenue Breakdown - U.S. revenues fell 1.9% year over year to $744.9 million, missing projections [3]. - International revenues increased by 0.8% year over year to $260.4 million, exceeding expectations [3]. Segmental Revenue Analysis - **Diagnostics**: Revenues increased by 0.8% year over year to $453.6 million, with a 4.5% increase excluding COVID-19 revenues [4]. - **Molecular Diagnostics**: Revenues of $326 million increased by 1.7% at constant exchange rates, aligning with projections [5]. - **Breast Health**: Revenues decreased by 7.4% year over year to $356.2 million, attributed to lower sales of mammography equipment [6]. - **GYN Surgical**: Revenues grew by 4.2% year over year to $162.5 million, surpassing expectations [7]. - **Skeletal Health**: Revenues declined by 21.8% year over year to $33 million, exceeding projections [8]. Operational Metrics - Adjusted gross margin increased by 40 basis points to 61.1%, while adjusted operating margin contracted by 40 basis points to 30% [9]. Cash and Debt Position - Cash and cash equivalents at the end of Q2 fiscal 2025 were $1.43 billion, down from $1.78 billion at the end of Q1 [10]. - Total long-term debt was $2.52 billion, slightly down from $2.53 billion in the previous quarter [10]. Future Outlook - For fiscal 2025, the company reiterated its revenue outlook of $4.05-$4.10 billion, indicating a year-over-year increase of 0.5%-1.7% [11]. - Adjusted EPS is now projected to be between $4.15 and $4.25, reflecting a downward revision from earlier estimates [12]. - For Q3 fiscal 2025, revenues are expected to be between $1 billion and $1.01 billion, suggesting a year-over-year decrease [12]. Market Context - The company’s performance has been impacted by a challenging economic environment, including tariff pressures and geopolitical conditions [14]. - Despite the challenges, Diagnostics revenues showed strength due to consistent demand in specific assay markets [15].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 29, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36214 __________________________________________________________ HOLOG ...

Company Overview - Hologic operates across three segments: Diagnostics (44%), Breast and Skeletal Health (40%), and Surgical (16%) [14] - The company's revenue is primarily driven by consumables (62%), followed by capital (19%) and service & other (19%) [14] - The US market accounts for 75% of Hologic's revenue, while international markets contribute 25% [14] Financial Performance and Growth - Hologic has demonstrated mid-single-digit total sales growth [17] - The company has achieved double-digit non-GAAP EPS growth [19] - Q2'25 revenue was $1,005.3 million, a decrease of 1.2% compared to Q2'24 [69, 71] - Hologic forecasts full year 2025 revenue between $4,050 million and $4,100 million, representing a 0.5% to 1.7% increase [74] - The company anticipates full year 2025 non-GAAP diluted EPS between $4.15 and $4.25, a 1.7% to 4.2% increase [74] Strategic Focus and International Expansion - Hologic aims to continue double-digit non-GAAP EPS growth, driven by mid-single-digit revenue growth, operating margin expansion, acquisitions, and buybacks [77] - International revenue has grown from $533 million in 2014 to $999 million in 2024 [51]

Core Insights - Hologic reported revenue of $1.01 billion for the quarter ended March 2025, reflecting a year-over-year decline of 1.2% but exceeding the Zacks Consensus Estimate of $1 billion by 0.34% [1] - The company's EPS was $1.03, unchanged from the same quarter last year, and surpassed the consensus estimate of $1.02 by 0.98% [1] Revenue Performance by Segment - Diagnostics - Cytology and perinatal: Revenue of $118.50 million, down 1.7% year-over-year, below the average estimate of $119.94 million [4] - Diagnostics - Molecular diagnostics: Revenue of $326 million, up 1% year-over-year, slightly below the average estimate of $328.58 million [4] - Diagnostics - Blood screening: Revenue of $9.10 million, a significant increase of 31.9% year-over-year, exceeding the average estimate of $4.99 million [4] - Breast health - Breast imaging: Revenue of $271.90 million, down 11.4% year-over-year, below the average estimate of $282.58 million [4] - Skeletal health: Revenue of $33 million, up 21.8% year-over-year, surpassing the average estimate of $18 million [4] - Total Breast health: Revenue of $356.20 million, down 7.4% year-over-year, below the average estimate of $369.50 million [4] - Total Diagnostics: Revenue of $453.60 million, up 0.8% year-over-year, slightly above the average estimate of $453.52 million [4] - GYN surgical: Revenue of $162.50 million, up 4.2% year-over-year, exceeding the average estimate of $161.11 million [4] - Breast health - Interventional breast solutions: Revenue of $84.30 million, up 8.2% year-over-year, below the average estimate of $86.91 million [4] Stock Performance - Hologic's shares have returned -3.9% over the past month, compared to a -0.7% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Viewpoint - Hologic reported quarterly earnings of $1.03 per share, exceeding the Zacks Consensus Estimate of $1.02 per share, with revenues of $1.01 billion, surpassing expectations by 0.34% [1][2]. Financial Performance - The company has surpassed consensus EPS estimates three times over the last four quarters [2]. - Hologic's revenues for the quarter ended March 2025 were $1.01 billion, compared to $1.02 billion a year ago [2]. - The earnings surprise for the recent quarter was 0.98%, with the company expected to post earnings of $1.02 per share but actually reporting $1.03 [1][2]. Stock Performance - Hologic shares have declined approximately 19.3% since the beginning of the year, while the S&P 500 has decreased by 5.3% [3]. - The current Zacks Rank for Hologic is 3 (Hold), indicating expected performance in line with the market in the near future [6]. Future Outlook - The consensus EPS estimate for the upcoming quarter is $1.10 on revenues of $1.03 billion, and for the current fiscal year, it is $4.27 on revenues of $4.08 billion [7]. - The outlook for the industry, particularly the Medical - Instruments sector, is favorable, ranking in the top 23% of over 250 Zacks industries [8].

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was $1,005 million, a decrease of 0.5% in constant currency, but at the upper end of guidance [7][8] - Non-GAAP earnings per share were $1.30, flat compared to the previous year, reflecting solid gross margin expansion and benefits from share buybacks [8][30] - Non-GAAP gross margin improved to 61.1%, up 40 basis points year-over-year [31][34] Business Line Data and Key Metrics Changes - Diagnostics revenue was $453.6 million, growing 1.5% or 5.2% excluding COVID-related sales, driven by molecular diagnostics [16][18] - Breast Health revenue declined 6.9% to $356.2 million, with a 9.2% decline organically, attributed to lower gantry placements [19][40] - Surgical revenue increased 5.1% to $162.5 million, with international surgical business growing 16.2% [23][24] - Skeletal revenue grew 22.9% to $33 million, exceeding internal expectations due to improved production [25] Market Data and Key Metrics Changes - The diagnostics division's growth was impacted by reduced HIV testing in Africa due to funding cuts, affecting overall performance [18] - Sales expectations for China were lowered due to geopolitical challenges, with anticipated revenue now at approximately $50 million for the fiscal year [14][66] Company Strategy and Development Direction - The company aims to accelerate growth in Breast Health and has reorganized its sales team to improve focus on capital and disposable product sales [20][21] - Strategic acquisitions, such as Endomagnetics and Gynasonics, are expected to enhance market position and drive future growth [13][35] - The company is exploring various mitigation strategies for tariff impacts, primarily from Costa Rica and China [27][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate the challenging macroeconomic environment and anticipates improved growth rates in the fourth quarter [14][43] - The company expects to return to healthy growth in Breast Health by Q4 2025, driven by better commercial execution and new product introductions [40][43] Other Important Information - The company generated $169.5 million in operating cash flow in Q2 and ended the quarter with over $1.6 billion in cash and investments [12][35] - The effective tax rate for Q2 was 19%, reflecting adjustments to align with the expected full-year rate [34] Q&A Session Summary Question: Can you discuss the potential higher costs from suppliers and mitigation efforts? - Management indicated that while there are discussions about potential price increases, they believe they can offset these costs through their existing operations in Costa Rica [46][47] Question: What is the current appetite for capital from hospitals? - Management noted that the breast health business has stabilized, and they expect hospitals to allocate budgets for meaningful product improvements [48][75] Question: How is the company addressing the decline in Africa and China? - The company is de-risking its revenue expectations from China and addressing funding cuts affecting testing in Africa [14][66] Question: What is the outlook for the Breast Health business? - Management is optimistic about returning to steady growth in Breast Health, with improvements expected in the fourth quarter [40][54] Question: Can you provide insights on the gantry replacement cycle? - The average life of gantries has extended to 10-12 years, and the company is actively managing an end-of-life strategy for older units [78] Question: How is the company managing supply chain challenges? - Management expressed confidence in their supply chain, particularly for US-manufactured products, while evaluating potential adjustments as needed [73][74]

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was $1,005 million, a decrease of 0.5% in constant currency, but at the upper end of guidance [5][6] - Non-GAAP earnings per share were $1.30, flat compared to the previous year, reflecting solid gross margin expansion and benefits from share buybacks [6][30] - Operating cash flow generated in Q2 was $169.5 million, with cash and equivalents at $1,430 million at quarter end [10][34] Business Line Data and Key Metrics Changes - Diagnostics revenue was $453.6 million, growing 1.5% or 5.2% excluding COVID-related sales, driven by molecular diagnostics [14][17] - Breast Health revenue declined 6.9% to $356.2 million, with a 9.2% organic decline, attributed to lower gantry placements [18][39] - Surgical revenue increased 5.1% to $162.5 million, with international surgical business growing 16.2% [21][22] - Skeletal revenue grew 22.9% to $33 million, benefiting from improved production ramp of the DEXA system [23] Market Data and Key Metrics Changes - The company lowered sales expectations for China due to geopolitical turbulence, now forecasting only about $50 million in revenue from China for fiscal 2025 [12][36] - The diagnostics business in Africa faced declines due to funding cuts, impacting overall growth [17][55] Company Strategy and Development Direction - The company aims to accelerate growth in Breast Health and has reorganized its sales team to improve performance [19][20] - Hologic is actively seeking acquisitions and investments, with a focus on tuck-in M&A and returning value to shareholders through stock repurchases [11][33] - The company is confident in its strong market positions in core US and European markets, despite challenges in other regions [12][41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver solid financial results despite macroeconomic challenges [5][6] - The company anticipates faster growth beginning in Q4 2025, driven by better commercial execution and new product introductions [12][36] - Management highlighted the importance of employee engagement and its role in navigating dynamic environments [10] Other Important Information - The company expects a gross impact of $20 to $25 million per quarter from recently announced tariffs, primarily affecting manufacturing in Costa Rica and China [26][27] - Non-GAAP gross margin improved to 61.1%, driven by strong diagnostics sales and the addition of EndoMag and Gynasonics [30] Q&A Session Summary Question: Impact of tariffs and supplier pricing - Management indicated that while there are potential higher costs from suppliers, they believe offsets will balance the impact [45][46] Question: Breast Health sales force reorganization - The reorganization aims to improve focus on capital and disposable product sales, with expectations of a more stable business moving forward [47][49] Question: Revenue guidance and Africa diagnostics weakness - The decline in revenue guidance is primarily due to reduced expectations from China and the impact of funding cuts in Africa [54][55] Question: Gantry replacement cycle - The average life of gantries has extended, and the company is in a replacement cycle, expecting steady placements moving forward [75][76] Question: Supply chain management - Management feels confident in their supply chain, with most manufacturing done in the US, and is evaluating options but not planning significant changes [69][71] Question: Molecular diagnostics contracting cycles - The molecular diagnostics business is expected to grow, despite headwinds from HIV testing declines in Africa [81][83]

Revenue Performance - Revenue for Q2 2025 was $1,005.3 million, a decrease of 1.2% compared to the prior year, but slightly above the guidance range of $995 to $1,005 million[2]. - Total revenues for the three months ended March 29, 2025, were $1,005.3 million, a slight decrease from $1,017.8 million for the same period in 2024, representing a decline of approximately 1.5%[22]. - Consolidated GAAP revenue for the three months ended March 29, 2025, was $1,005.3 million, a slight decrease of 1.5% compared to $1,017.8 million in the prior year[29]. - Organic revenue excluding COVID-19 for the six months ended March 29, 2025, was $1,902.5 million, a decrease of 0.4% from $1,909.3 million in the same period of 2024[29]. Earnings and Profitability - GAAP diluted EPS was a loss of ($0.08), down from $0.72 in the prior year, while non-GAAP diluted EPS was $1.03, flat compared to the prior year and at the high end of guidance[2][4]. - Net income for the three months ended March 29, 2025, was a loss of $17.4 million, compared to a net income of $169.9 million for the same period in 2024, indicating a significant decrease[22]. - GAAP net income for the three months ended March 29, 2025, was a loss of $17.4 million, while the previous year showed a profit of $169.9 million[31]. - Non-GAAP net income for the six months ended March 29, 2025, was $471.5 million, compared to $480.5 million in the same period last year[31]. - Adjusted EBITDA for the six months ended March 29, 2025, was $651.9 million, compared to $650.6 million in the prior year[31]. Revenue Segmentation - Diagnostics revenue increased by 0.8% to $453.6 million, primarily driven by higher molecular diagnostics sales, while organic diagnostics sales excluding COVID-19 grew by 4.5%[2][5]. - Breast Health revenue decreased by 7.4% to $356.2 million, primarily due to lower sales of mammography capital equipment[2][5]. - Surgical revenue grew by 4.2% to $162.5 million, driven by the addition of the acquired Gynesonics business and strong international sales[2][5]. Expenses and Costs - Operating expenses for the three months ended March 29, 2025, totaled $384.3 million, an increase from $331.9 million in the same period in 2024, marking an increase of approximately 15.7%[22]. - Research and development expenses for the three months ended March 29, 2025, were $61.5 million, down from $74.6 million in the same period in 2024, representing a decrease of about 17.5%[22]. - GAAP gross margin decreased by 1,580 basis points to 37.5%, primarily due to impairment charges on intangible assets[10]. Cash Flow and Financial Position - Cash flow from operations was $169.5 million, with cash and cash equivalents at $1.43 billion at the end of the quarter[10]. - Cash and cash equivalents at the end of the period were $1,429.5 million, down from $2,180.0 million, representing a decrease of 34.4%[26]. - Total assets decreased to $8,545.1 million from $9,156.0 million, a decline of approximately 6.7%[24]. - Total current liabilities decreased to $989.7 million from $1,037.2 million, a reduction of approximately 4.6%[24]. Shareholder Actions - The company repurchased 3.0 million shares for $200 million during the quarter[2]. - Repurchases of common stock amounted to $717.3 million during the six months ended March 29, 2025, compared to $676.8 million in the prior year[26]. Guidance and Future Expectations - Full-year revenue guidance for fiscal 2025 is maintained at $4,050 - $4,100 million, while non-GAAP EPS guidance is slightly lowered to $4.15 - $4.25[7][9]. - The company expects GAAP net income per share for the quarter ending June 28, 2025, to be between $0.85 and $0.88[33]. Impairment and Charges - The impairment of intangible assets for the three months ended March 29, 2025, was $183.4 million, significantly higher than $25.9 million for the same period in 2024[22]. - The company reported an impairment charge of $220.9 million for intangible assets during the six months ended March 29, 2025[26]. Return on Investment - Adjusted Return on Invested Capital (ROIC) was 13.7%, an increase of 30 basis points compared to the prior year[10]. - Adjusted return on invested capital (ROIC) for the trailing twelve months ended March 29, 2025, was 13.7%[35]. Geographic Revenue Breakdown - Geographic revenue breakdown for the three months ended March 29, 2025: United States 74.1%, Europe 14.6%, Asia-Pacific 5.9%, and Rest of World 5.4%[38].

Core Insights - Hologic (HOLX) is expected to report quarterly earnings of $1.02 per share, reflecting a year-over-year decline of 1% and revenues of $1 billion, which is a 1.6% decrease compared to the previous year [1] - The consensus EPS estimate has been adjusted downward by 0.1% over the past 30 days, indicating a reassessment by analysts [2] - Changes in earnings estimates are crucial for predicting investor reactions, with empirical studies showing a strong correlation between earnings estimate revisions and short-term stock performance [3] Revenue Estimates - Analysts project 'Revenues- Diagnostics- Cytology and Perinatal' at $119.94 million, a decrease of 0.5% year-over-year [5] - 'Revenues- Diagnostics- Molecular Diagnostics' is estimated to be $328.58 million, reflecting an increase of 1.8% from the prior year [5] - 'Revenues- Diagnostics- Blood Screening' is expected to reach $4.99 million, indicating a significant decline of 27.6% [6] - 'Revenues- Breast Health- Breast Imaging' is projected at $282.58 million, down 7.9% from the previous year [6] - 'Revenue- Skeletal Health' is estimated at $18.00 million, showing a decline of 33.6% [6] - Total Breast Health revenue is expected to be $369.50 million, a decrease of 3.9% year-over-year [7] - Total Diagnostics revenue is projected at $453.52 million, reflecting a slight increase of 0.8% [7] - 'Revenue- GYN Surgical' is estimated to reach $161.11 million, indicating a growth of 3.3% [7] - 'Revenues- Breast Health- Interventional Breast Solutions' is expected to be $86.91 million, showing an increase of 11.6% from the prior year [8] Stock Performance - Over the past month, Hologic shares have declined by 5.4%, compared to a 4.3% decline in the Zacks S&P 500 composite [8] - Hologic holds a Zacks Rank 3 (Hold), suggesting that its performance is likely to align with the overall market in the near term [8]